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While treatment strategies for non-small cell lung cancer (NSCLC) has made 
substantial progress in the past two decades with the advent of molecular targeted 
agents and immune checkpoint inhibitors, advances in the field of small cell lung 
cancer (SCLC) have been relatively dismal. The mainstay of treatment for advanced 
SCLC remains platinum-based doublet chemotherapy in the first line setting, with 
rechallenge of chemotherapy during relapse for platinum-sensitive disease. In the 
platinum resistant or refractory settings, there are no standard guidelines for 
treatment, with various phase II studies showing similar response rates (RR) and 
survival outcomes for different single agent chemotherapies, including topotecan, 
irinotecan, taxanes and gemcitabine (1).  
 
Multiple molecularly targeted agents have been assessed in SCLC with limited 
success in improving patient outcomes beyond platinum doublet chemotherapy. One 
of the earliest mechanisms targeted in SCLC was angiogenesis since high vascular 
endothelial growth factor (VEGF) levels were found to be a poor prognostic marker 
for SCLC, and preclinical studies supported the use of anti-VEGF agents to improve 
tumor responses (2). However, subsequent phase II/III trials undertaken with 
different anti-VEGF antibodies or small molecule inhibitors were negative, resulting 
in the discontinuation of anti-VEGF clinical development in SCLC (3). Other signaling 
pathways have also been assessed in SCLC, including targeted agents against the 
phosphatidylinostinol 3-kinase (PI3K) pathway and critical apoptotic substrates, such 
as BCL2. Despite strong evidence of antitumor activity in pre-clinical studies, phase 
II trials have nevertheless been negative (Figure 1) (4). 
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George and co-workers assessed whole genome sequencing data from 110 SCLC 
primary tumors, which found that TP53 and RB1 loss were almost universal (100% 
and 93%, respectively) (5). However, TP53 and RB1 are both notoriously 
challenging to target and are currently not actionable. Interestingly, inactivating 
mutations in the Notch family were noted in approximately 25% of SCLC tumors, 
with Notch activation in LSL-N2ICD mice leading to tumor reduction. The Notch 
signalling pathway has been shown to be important for the control of neuroendocrine 
differentiation, and its inhibition may be mediated by DLL3 through ASCL1 (6). 
 
Another promising target, poly(ADP-ribose) polymerase (PARP), has been shown in 
proteomic profiling studies to be dysregulated in SCLC (7). There has already been 
much success in exploiting the concept of synthetic lethality through the inhibition of 
PARP in BRCA1/2 mutated ovarian and breast cancers (8, 9) The use of PARP 
inhibitors in SCLC is currently being investigated in the maintenance setting for 
patients who have responded to first line chemotherapy (ISRCTN73164486), and 
also in the first line setting in combination with cisplatin/etoposide (NCT01642251).  
 
Molecular analysis has also found that genomic signatures of SCLC are similar to 
those associated with tobacco exposure (10), in keeping with the fact that SCLC is 
almost universally associated with smoking. In addition, studies characterising the 
genomic landscape of different cancers have placed SCLC among those with the 
highest mutational load, with a non-synonymous mutation rate of 5.5 to 7.4/Mb (11). 
Importantly, there is increasing evidence that mutational load is a predictor of 
response to novel immunotherapeutic agents. Subsequent clinical studies involving 
immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte associated 
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protein 4 (CTLA4) and anti-programmed cell death 1 (PD-1) therapies have shown 
promising efficacy. Ipilimumab in combination with carboplatin/paclitaxel in the first 
line setting for extensive stage (ES) SCLC has shown that phased ipilimumab 
improved immune-related PFS (irPFS) compared to chemotherapy alone (hazard 
ratio 0.64, p=0.03) (12). In the subgroup of patients with SCLC in the KEYNOTE-028 
study treated with pembrolizumab, patients with programmed cell death-ligand-1 
(PD-L1) positive tumors had RR of up to 35%, indicating that RR with 
immunotherapy could be improved with better patient selection criteria (13). 
 
In addition, evidence has suggested that the dual blockade of PD-1 and CTLA-4 
pathways may have synergistic outcomes due to the inhibition of non-redundant 
mechanisms in immune suppression (14, 15). Most recently, the CHECKMATE-032 
study showed that combination therapy with nivolumab and ipilimumab is more 
effective than nivolumab monotherapy, with a RR of 23%, mPFS of 3.4 months and 
1-year OS of 43% (16). More importantly, survival curves suggest that there could be 
a long tail, indicating that some patients are experiencing durable responses; it will 
be interesting to see if these promising data persist with longer follow up. A phase III 
study is currently investigating the utility of combined immune checkpoint inhibition 
as maintenance therapy in patients who achieved at least stable disease after four 
cycles of standard first line platinum doublet chemotherapy (NCT02538666). 
 
In the article published by Gapanova and colleagues in Clinical Cancer Research 
(17), the authors report that a novel inhibitor-drug conjugate, STA-8866, produced 
impressive preclinical results in terms of tumor shrinkage and survival in SCLC 
xenograft and patient-derived xenograft (PDX) models. STA-8666 is a tripartite 
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molecule where a heatshock protein-90 (HSP90)-targeting moiety is conjugated via a 
cleavable carbamate linker to SN38, the metabolite of irinotecan. The rationale for 
drug efficacy is based on the understanding that HSP90 is highly expressed in tumor 
cells compared to normal tissue, thus allowing STA-8666 to deliver drug at higher 
concentrations to the tumor. 
 
In this study, xenograft and PDX models of SCLC were treated with single agent 
STA-8666 at varying doses, combination treatment with STA-8666 plus carboplatin, 
and other cytotoxic regimens including irinotecan, topotecan, etoposide, carboplatin, 
ganetespib (a HSP90 inhibitor), and carboplatin/etoposide. The study showed robust 
activity of STA-8666 both as monotherapy at 150mg/kg and in combination at 
50mg/kg with carboplatin in the NCI-H69 xenograft model, where tumors showed 
regression below the detectable range in all mice after 3 doses of treatment (6/6 in 
single agent, 11/11 in combination treatment). Durable responses were observed, 
with 3/6 mice showing no recurrence with STA-8666 monotherapy over 3 months, 
while 6/11 mice had no recurrence within 120 days with combination treatment. 
Importantly, disease recurrence was controlled by repeated administrations of STA-
8666, with rapid tumor regression to undetectable levels upon treatment rechallenge.  
 
Pharmacokinetic and pharmacodynamics studies showed that STA-8666 is highly 
concentrated in tumor tissue both in cleaved and uncleaved form, indicating the 
potential for continued SN38 release. Immunohistochemistry (IHC) analysis of tumor 
samples at different timepoints also support the presence of persistent necrosis post 
treatment. Studies of the downstream effects of STA-8666 demonstrated activity 
against kinases involved in DNA damage and cell cycle checkpoint involved in G2/M 
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phase arrest, confirming its mechanistic role in causing cell death. Taken together, 
these results support the fact that STA-8666 is highly effective both as monotherapy 
and in combination with carboplatin for the treatment of SCLC, and will warrant 
clinical studies to validate these findings. 
 
The use of irinotecan as a cytotoxic in treatment of SCLC has been well studied, 
providing good scientific rationale for the use of STA-8666 in this setting, with its 
drug conjugate SN38, an active metabolite of irinotecan. While several phase II 
studies support the use of irinotecan for the treatment of SCLC in the relapsed 
setting (18), its role in the first line setting is somewhat controversial. The initial 
Japan Clinical Oncology Group (JCOG) study by Noda and co-workers showed 
superior survival in patients with ES SCLC treated with the combination of 
cisplatin/irinotecan versus cisplatin/etoposide (p=0.002), with an improvement in RR 
from 67% to 84% (p=0.02) (19). Nonetheless, three further studies carried out in 
Western populations in Europe and North America were unable to recapitulate such 
an improved survival (20-22), The combination of platinum with etoposide has 
therefore remained the standard of care in the first line setting for ES SCLC. 
Regardless, irinotecan monotherapy remains a viable treatment option in the setting 
of relapsed SCLC, with efficacy rates similar to other single agent treatments. 
 
Recently, various other drug conjugates including antibody-drug conjugates (ADCs) 
such as lorvotuzumab mertansine and rovalpituzumab tesirine have been studied in 
SCLC. Rovalpitizumab tesirine is a humanised anti-delta-like 3 (DLL3) monoclonal 
antibody conjugated to pyrrolobenzodiazepine (PDB) dimer toxin that binds to a DNA 
minor groove resulting in DNA damage (23). It showed a RR of 16% and disease 
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control rate (DCR) of 31% in a phase Ib trial involving patients with relapsed SCLC 
and large cell neuroendocrine cancer. Looking at the subgroup of patients deemed 
to be DLL3-positive (tumor DLL3 expression in ≥50% of tumor cells by IHC), the RR 
and DCR improved to 31% and 85%, respectively (24). More importantly, antitumor 
responses were seen in both the platinum sensitive and resistant/refractory settings. 
The drug was generally well tolerated, with thrombocytopenia and serosal effusion 
being the most common grade 3 adverse events. Another ADC that has been 
assessed in SCLC is lorvotuzumab mertansine, involving a CD56 binding antibody 
conjugated to a microtubulin inhibitor DM-1. While preclinical and phase I data for 
lorvotuzumab mertansine appeared promising, the phase II trial investigating its role 
in combination with carboplatin/etoposide in the first line SCLC setting was 
discontinued due to a lack of efficacy and possible increased risk of infection and 
infection-related deaths (25).  
 
While STA-8666 has been shown to be highly efficacious in the pre-clinical setting in 
the study by Gapanova and colleagues (17), numerous therapies tested in SCLC 
over the past decade have time and again demonstrated that robust preclinical data 
do not necessarily translate into clinical success. Apart from the examples already 
discussed in this article, other targeted therapies such as vismodegib, an inhibitor of 
the Hedgehog pathway (26), and ABT-263, a BCL2 inhibitor (27), have similarly 
shown high efficacy in PDX models, but subsequently failed in clinical trials. 
Strategies to bridge this valley of death between the preclinical and clinical settings 
are clearly needed urgently.  
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Besides the inherent differences in mouse models and human subjects, another 
possible reason for the high drug attrition rates in late stage SCLC clinical studies 
could be due to the fact that it has been challenging to recapitulate the multitude of 
genetic aberrations found in human tumors of SCLC in genetically engineered 
mouse models (GEMMs) (4). For example, the complexity of genetic and epigenetic 
changes brought about by carcinogens in tobacco smoke may not be reflected in 
these GEMMs, resulting in the simplification of oncogenic pathways involved and an 
oversight of possible bypass mechanisms employed by tumors to escape cell death. 
Nevertheless, in the absence of better animal models, such GEMMs remain the best 
surrogate for preclinical studies in the current setting. 
 
Many drugs that have been combined with first line therapy with platinum/etoposide 
treatment have failed to show improved outcomes, likely due to the fact that SCLC is 
a highly chemosensitive tumor with impressive RR of 70-85% (28), making it 
challenging to improve such outstanding outcomes without additional significant 
toxicities. Therefore, rather than combine STA-8666 with chemotherapy in the 
advanced SCLC setting, STA-8666 should be investigated in a maintenance setting 
to improve PFS and delay the inevitable relapse seen in patients with SCLC.   
 
Looking to the future, the next steps forward for STA-8666 will be crucial in 
establishing its niche registration space in an ever expanding armamentarium of 
novel trial agents that are being assessed along the SCLC treatment pathway. 
Ultimately, the challenge now is to determine how best to exploit our improved 
understanding of the biology of SCLC and the new range of antitumor agents 
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available in the clinic, and to translate them into meaningful management strategies 
to improve treatment outcomes in this disease of urgent unmet need. 
 
Acknowledgements 
The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute 
of Cancer Research is supported in part by a programme grant from Cancer Research UK. 
Support is also provided by the Experimental Cancer Medicine Centre (to The Institute of 
Cancer Research) and the National Institute for Health Research Biomedical Research 
Centre (jointly to the Royal Marsden NHS Foundation Trust and The Institute of Cancer 
Research). 
Disclosures 
TAY has received research support from AstraZeneca and Merck, and has served on 
Advisory Boards and received travel support from Pfizer and Bristol Myers Squibb. 
 
 10 
References 
1. Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 
2015;121(5):664-72. 
2. Blackhall FH, Shepherd FA. Angiogenesis inhibitors in the treatment of small cell and non-
small cell lung cancer. Hematol Oncol Clin North Am. 2004;18(5):1121-41, ix. 
3. Sharp A, Bhosle J, Abdelraouf F, Popat S, O'Brien M, Yap TA. Development of molecularly 
targeted agents and immunotherapies in small cell lung cancer. Eur J Cancer. 2016;60:26-39. 
4. Bunn PA, Jr., Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, et al. Small Cell Lung 
Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved 
Outcomes? J Thorac Oncol. 2016;11(4):453-74. 
5. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of 
small cell lung cancer. Nature. 2015;524(7563):47-53. 
6. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, et al. Targeting Notch, Hedgehog, 
and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445-64. 
7. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling 
identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including 
PARP1. Cancer Discov. 2012;2(9):798-811. 
8. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-
ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced 
breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-44. 
9. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral 
poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and 
recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-51. 
10. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, et al. A small-cell 
lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463(7278):184-90. 
11. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of 
mutational processes in human cancer. Nature. 2013;500(7463):415-21. 
12. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in 
combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung 
cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 
2013;24(1):75-83. 
13. Ott PA, M.E.E. F, Hiret S, Kim D, Moss RA, Winser T, et al. Pembrolizumab (MK-3475) in 
patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy 
results from KEYNOTE-028. J Clin Oncol. 2016;33(suppl;abstr7502). 
14. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 
combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 
2013;73(12):3591-603. 
15. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 
and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543-
53. 
16. Antonia SJ, Lopez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and 
nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-
label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883-95. 
17. Gaponova AV, Nikonova A, Deneka AY, Kopp MC, Kudinov AE, Skobeleva N, et al. A novel 
HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC). Clin 
Cancer Res. 2016. 
18. Sevinc A, Kalender ME, Altinbas M, Ozkan M, Dikilitas M, Camci C, et al. Irinotecan as a 
second-line monotherapy for small cell lung cancer. Asian Pac J Cancer Prev. 2011;12(4):1055-9. 
 11 
19. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus 
cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 
2002;346(2):85-91. 
20. Lara PN, Jr., Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of 
irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: 
clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530-5. 
21. Chen G, Huynh M, Fehrenbacher L, West H, Lara PN, Jr., Yavorkovsky LL, et al. Phase II trial of 
irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol. 
2009;27(9):1401-4. 
22. Hanna N, Bunn PA, Jr., Langer C, Einhorn L, Guthrie T, Jr., Beck T, et al. Randomized phase III 
trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated 
extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24(13):2038-43. 
23. Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-
targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating 
cells in vivo. Sci Transl Med. 2015;7(302):302ra136. 
24. Rudin CM, Pietanza MC, Bauer TM, Spigel D, Ready N, Morgensztern D, et al. Safety and 
efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted 
antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). J Clin Oncol. 
2016;34(suppl; abstr LBA8505). 
25. Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, et al. 
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity 
against small cell lung cancer in human xenograft models. MAbs. 2014;6(2):556-66. 
26. Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, et al. Vismodegib or 
cixutumumab in combination with standard chemotherapy for patients with extensive-stage small 
cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 
2016;122(15):2371-8. 
27. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, et al. Phase II 
study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small 
cell lung cancer. Clin Cancer Res. 2012;18(11):3163-9. 
28. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung 
cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen 
without this alkylating agent. Br J Cancer. 2000;83(1):8-15. 
 
 12 
 
 
Figure 1 : Therapeutic agents under assessment/previously tested in small cell lung 
cancer according to predominant mechanism of action. Furthest phase of clinical trial 
for each agent in square brackets.  Ongoing and recruiting studies in bold with 
clinical trials identifier numbers in brackets.  
 
